Log In
Print
BCIQ
Print
Print this Print this
 

Mesupron (WX-671)

  Manage Alerts
Collapse Summary General Information
Company Wilex AG
DescriptionSecond-generation serine protease inhibitor targeting urokinase-type plasminogen activator (uPA)
Molecular Target Urokinase-type plasminogen activator (PLAU) (uPA) ; Serine protease
Mechanism of ActionSerine protease inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$22.1M

$1.0M

$14.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today